Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person Nonconserved miR-608 suppresses prostate cancer progression through RAC2/PAK4/LIMK1 and BCL2L1/caspase-3 pathways by targeting the 3'-UTRs of RAC2/BCL2L1 and the coding region of PAK4

Class:IdLiteratureReference:9691785
_displayNameNonconserved miR-608 suppresses prostate cancer progression through RAC2/PAK4/LIMK1 and BCL2L1/caspase-3 pathways by targeting the 3'-UTRs of RAC2/BCL2L1 and the coding region of PAK4
_timestamp2020-06-19 15:45:15
author[Person:9691788] Zhang, Xu
[Person:9691783] Fang, Jiajie
[Person:4006069] Chen, Shiming
[Person:9691786] Wang, Weiyu
[Person:9691791] Meng, Shuai
[Person:9691784] Liu, Ben
created[InstanceEdit:9691792] Orlic-Milacic, Marija, 2020-06-19
journalCancer Med
pages5716-5734
pubMedIdentifier31389670
titleNonconserved miR-608 suppresses prostate cancer progression through RAC2/PAK4/LIMK1 and BCL2L1/caspase-3 pathways by targeting the 3'-UTRs of RAC2/BCL2L1 and the coding region of PAK4
volume8
year2019
(literatureReference)[Reaction:9014294] RAC2 binds effectors at the plasma membrane [Homo sapiens]
[Change default viewing format]
No pathways have been reviewed or authored by Nonconserved miR-608 suppresses prostate cancer progression through RAC2/PAK4/LIMK1 and BCL2L1/caspase-3 pathways by targeting the 3'-UTRs of RAC2/BCL2L1 and the coding region of PAK4 (9691785)